Theravance Biopharma is a biopharmaceutical company primarily focused on discovering, developing and commercializing respiratory medicines. The company was formed following the split of the erstwhile Theravance into two listed companies in June 2014 - Innoviva, Inc. (then Theravance, Inc.) and Theravance.?
| Revenue (Most Recent Fiscal Year) | $64.38M |
| Net Income (Most Recent Fiscal Year) | $-56.42M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.12 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.80 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -74.08% |
| Net Margin (Trailing 12 Months) | -89.38% |
| Return on Equity (Trailing 12 Months) | -32.37% |
| Return on Assets (Trailing 12 Months) | -16.48% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.77 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.77 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.32 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.27 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.15 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.18 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 50.00M |
| Free Float | 46.55M |
| Market Capitalization | $465.01M |
| Average Volume (Last 20 Days) | 0.28M |
| Beta (Past 60 Months) | -0.10 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 99.10% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |